The Factors Associated to Changes in the Glomerular Filtration Rate in Chronic Kidney Disease
Article Sidebar
Main Article Content
Abstract
Background: Chronic kidney disease is a common condition that affects patients' quality of life, especially in stages 3 and 4. Controlling various risk factors such as blood pressure, urine albumin, and hematocrit levels is important in slowing changes in the glomerular filtration rate (GFR). Identifying factors that influence GFR changes at this stage is essential for developing care and treatment methods for patients with chronic kidney disease.
Objective: To study factors related to changes in the glomerular filtration rate (GFR) of patients with chronic kidney disease in Sangkha District, Surin Province, in the year 2023.
Study design: This Retrospective Cohort study utilized data from 268 patients with chronic kidney disease stages 3 and 4 who received treatment at Sangkha Hospital, Surin Province, from October 1, 2022, to September 30, 2023. Collected data included age, gender, duration of diabetes, systolic and diastolic blood pressure, HbA1c levels, hematocrit, BMI, and urinalysis results. Univariate and multivariate linear regression analyses were used to assess the relationships between various factors and changes in GFR.
Results: Univariate analysis indicated that systolic blood pressure, urine albumin, and hematocrit were significantly associated with changes in GFR. Systolic blood pressure (Coefficient = 0.1, p-value = 0.019) and urine albumin (Coefficient = 1.3, p-value = 0.000) showed a positive correlation with changes in eGFR, while hematocrit (Coefficient = -0.2, p-value = 0.020) exhibited a significant negative correlation with changes in eGFR in patients with chronic kidney disease.
Conclusion: Controlling blood pressure, monitoring urine albumin, and managing anemia are crucial for slowing the decline in glomerular filtration rate in patients with chronic kidney disease.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67(6):2089-100. doi: 10.1111/j.1523-1755.2005.00365.x.
Ingsathit A, Thakkinstian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant 2010;25(5):1567-75. doi: 10.1093/ndt/gfp669.
Kanjanabuch T, Takkavatakarn K. Global Dialysis Perspective: Thailand. Kidney 360 2020;1(7):671-5. doi: 10.34067/KID.0000762020.
Jongudomsuk P, Srithamrongsawat S, Patcharanarumol W, Limwattananon S, Pannarunothai S, Vapatanavong P, et al. The Kingdom of Thailand Health System Review. Health Syst Transit 2015;5(5):1-326.
Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116(1):85-97. doi: 10.1161/CIRCULATIONAHA.106.678342.
Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008;74(7):867-72. doi: 10.1038/ki.2008.350.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60. doi: 10.1056/NEJMoa011303.
Kostourou DT, Milonas D, Polychronopoulos G, Sofogianni A, Tziomalos K. The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy. J Pers Med 2022;12(8):1253. doi: 10.3390/jpm12081253.
Green SB. How Many Subjects Does It Take To Do A Regression Analysis. Multivariate Behav Res 1991;26(3):499-510. doi: 10.1207/s15327906mbr2603_7.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019.
Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. Diabetes Obes Metab 2016;18(2):169-77. doi: 10.1111/dom.12600.
Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375(9731):2073-81. doi: 10.1016/S0140-6736(10)60674-5.
Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139(2):137-47. doi: 10.7326/0003-4819-139-2-200307150-00013.
Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011;80(1):93-104. doi: 10.1038/ki.2010.531.
Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009;4(1):57-61. doi: 10.2215/CJN.01670408.
Thomas MC, Tsalamandris C, MacIsaac RJ, Jerums G. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am J Kidney Dis 2006;48(4):537-45. doi: 10.1053/j.ajkd.2006.06.011.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615-25. doi: 10.2337/diabetes.54.6.1615.
Kalantar-Zadeh K, Kramer HM, Fouque D. High-protein diet is bad for kidney health: unleashing the taboo. Nephrol Dial Transplant 2020;35(1):1-4. doi: 10.1093/ndt/gfz216.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383(23):2219-29. doi: 10.1056/NEJMoa2025845.
